Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Healthcare Medical Devices
Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > Ascend update very soon before or after news FDA V4.0 ?🚀
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(12)
•••
Post by jopatcloon Jul 11, 2024 12:58pm
103 Views
Post# 36128588

Ascend update very soon before or after news FDA V4.0 ?🚀

Ascend update very soon before or after news FDA V4.0 ?🚀good comment and see  beautiful picture on thie post Learn more about our imaging workflows here:
https://lnkd.in/gDMsFGff
 With the VentriPoint integration,
@cardinal Where is thee sales and demo team this week.
 
9
from #vpt, 
 
@cardinal Should hear Ascend update very soon
 
10
from #vpt, 

Open Integration with specialized AI algorithms

  • Seamlessly integrate specialized AI algorithms with our diagnostic viewer, InView, to improve diagnosis and monitoring of fetal, pediatric, and adult congenital heart disease
  • With the VentriPoint integration, generate 3D models of the heart’s chambers from Echo imaging for reproducible and accurate volumetric measurements and ejection fractions
VentriPoint-screenshot

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities